Ibrutinib does not reverse disease- and treatment-related hypogammaglobulinaemia associated with chronic lymphocytic leukemia

Immunomodulation mediated by polyclonal IgG replacement in patients with chronic lymphocytic leukemia may be important in infection prevention

“…Our previously published retrospective analysis on 29 ibrutinib‐treated CLL patients found that although long‐term use of BTKi was not associated with serious infectious episodes, it neither reversed pre‐existing hypogammaglobulinemia nor affected overall survival 4 . Three patients required IgRT given via SCIg (once weekly, treatment duration 3–11 years until 2020).…”